Vijay Rao
Cardiovascular Disease · Indianapolis, INNPI 1811158488
Payments from drug & device makers
Across 634 payments — averaging $1113.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$398K
- Boehringer Ingelheim$63K
- Merck$45K
- Lilly USA, LLC$36K
- Esperion Therapeutics, Inc.$34K
- Boehringer Ingelheim International GmbH$33K
- plus $98K from 24 others
Across 1 payment — averaging $5625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6K
What the payments were for
- Consulting fees$7,0653%
- Speaking & faculty fees$222,96890%
- Travel & lodging$7,7683%
- Food & beverage$9,4484%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 119 | $397,643 |
| Boehringer Ingelheim | 80 | $62,703 |
| Merck | 34 | $44,977 |
| Lilly USA, LLC | 33 | $35,823 |
| Esperion Therapeutics, Inc. | 58 | $33,648 |
| Boehringer Ingelheim International GmbH | 86 | $33,181 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $28,838 |
| Pfizer | 75 | $27,764 |
| Scpharmaceuticals Inc. | 22 | $18,430 |
| Amgen | 10 | $10,194 |
| AstraZeneca | 14 | $8,993 |
| E.r. Squibb & Sons, L.L.C. | 18 | $539 |
| Johnson & Johnson(2 entities) | 34 | $465 |
| Abbott | 3 | $422 |
| Artivion, Inc. | 1 | $400 |
| Novo Nordisk | 10 | $305 |
| Cvrx, Inc. | 2 | $302 |
| Akcea Therapeutics, Inc. | 1 | $156 |
| Abiomed | 1 | $152 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $147 |
| Alnylam Pharmaceuticals Inc. | 2 | $146 |
| Elekta, Inc. | 1 | $140 |
| Sanofi-aventis U.S. LLC | 8 | $118 |
| Boston Scientific | 3 | $53 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 2 | $30 |
| Bayer | 2 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Lantheus Medical Imaging, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$90,500
- ENTRESTO$69,446
- VERQUVO$35,159
- FUROSCIX$18,218
- VYNDAQEL$17,274
- ELIQUIS$9,512
- TRULICITY$7,125
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER$400
- Barostim Neo System$302
- CARDIOMEMS$175
- TEGSEDI$156
- Impella$152
- ELEKTA MEDICAL LINEAR ACCELERATOR$140
- AMVUTTRA$133
- HeartMate 3 Left Ventricular Dev$127
- OPDIVO$125
- Mitra Clip system$120
- SYNJARDY$110
- Ozempic$109
- INVOKANA$102
How this compares
$705,687 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 518 | $688,259 |
| EntrestoSacubitril/Valsartan | 435 | $581,042 |
| JardianceEmpagliflozin | 322 | $397,155 |
| XareltoRivaroxaban | 85 | $101,235 |
| Repatha SureclickEvolocumab | 66 | $71,007 |
| FarxigaDapagliflozin Propanediol | 55 | $64,126 |
| VascepaIcosapent Ethyl | 24 | $21,080 |
| BrilintaTicagrelor | 32 | $16,929 |
| Praluent PenAlirocumab | 22 | $16,066 |
| Verapamil Er PmVerapamil Hcl | 12 | $8,715 |
| Midodrine Hcl | 66 | $6,541 |
| Metoprolol Succinate | 582 | $6,469 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 196 | $5,734 |
| Carvedilol | 710 | $5,037 |
| Torsemide | 224 | $4,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27,764 | $688,259518 claims |
| NovartisEntresto | $397,643 | $581,042435 claims |
| Boehringer IngelheimJardiance | $62,703 | $397,155322 claims |
| Johnson & JohnsonXarelto | $465 | $101,23585 claims |
| AstraZenecaFarxiga, Brilinta | $8,993 | $81,05487 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Roopa RaoIndianapolis$481K
- Julie ClaryIndianapolis$475K
- James TrippiIndianapolis$449K
- John MillerIndianapolis$354K
- Richard KovacsIndianapolis$338K
- David KovacichIndianapolis$327K
- Jose Emanuel FinetIndianapolis$299K
- George LolayIndianapolis$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.